Publicaciones científicas

Influence of morbid obesity and insulin resistance on gene expression levels of AQP7 in visceral adipose tissue and AQP9 in liver

Victoria Catalán (1,6), Javier Gómez-Ambrosi (1,6), Carlos Pastor (2), Fernando Rotellar (2,6), Camilo Silva (3,6), Amaia Rodríguez (1,6), María J. Gil (4,6), Javier A. Cienfuegos (2,6), Javier Salvador (5,6), Joan Vendrell (5,7) and Gema Frühbeck (1,3,6) 
(1) Metabolic Research Laboratory, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain
(2) Department of Surgery, Clínica Universitaria de NavarraUniversity of Navarra, Pamplona, Spain
(3) Department of Endocrinology, Clínica Universitaria de Navarra, University of Navarra, Avda. Pío XII, 36, 31008 Pamplona, Spain
(4) Department of Biochemistry, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain
(5) Endocrinology and Research Unit, Hospital Universitari de Tarragona Joan XXIII, Rovira i Virgili University, Tarragona, Spain
(6) CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain
(7) CIBER Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain

Revista: Obesity Surgery

Fecha: 01/06/2009

Cirugía General y Digestiva Bioquímica Clínica Endocrinología y Nutrición Área de Obesidad

BACKGROUND
Glycerol production and its efflux from adipocytes to the liver are key to modulate lipid and glucose homeostasis. Aquaporin 7 (AQP7) is an aquaglyceroporin that acts as the adipose glycerol channel, whereas aquaporin 9 (AQP9) is the specific channel operating in the liver. The aim of the present work was to evaluate the effect of obesity and type 2 diabetes mellitus (T2DM) on gene expression levels of AQP7 in visceral adipose tissue (VAT) and AQP9 in liver.

METHODS
VAT and liver biopsies obtained from 20 women were used in the study. Patients were classified as lean or obese with the last group being further subclassified as normoglycemic (NG), patients with impaired glucose tolerance (IGT), or with T2DM. Anthropometric measurements as well as circulating metabolites, hormones, and adipokines were determined. Real-time polymerase chain reaction analyses were performed to quantify transcript levels of AQP7 in VAT and AQP9 in the liver.

RESULTS
Gene expression levels of AQP7 in VAT showed a tendency toward an increase (P = 0.065) in obese patients (both NG and T2DM) compared to lean subjects. AQP9 showed a significant downregulation in the hepatic biopsies obtained from obese T2DM patients compared to obese NG and IGT patients (P = 0.028).

CONCLUSION
The tendency toward an elevation of mRNA expression of VAT AQP7 in obesity together with the decreased hepatic AQP9 expression observed in obese T2DM subjects suggests a potential role in facilitating glycerol release from adipose tissue and reducing glycerol entry into hepatocytes in obesity and T2DM, respectively.

CITA DEL ARTÍCULO Obes Surg. 2008 Jun;18(6):695-701

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra